

Stephen J Richards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6425321/publications.pdf>

Version: 2024-02-01

82
papers

6,861
citations

101384

36
h-index

69108

77
g-index

85
all docs

85
docs citations

85
times ranked

5433
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. <i>Lancet Haematology</i> , 2022, 9, e553-e556.	2.2	6
2	The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018. <i>European Journal of Haematology</i> , 2021, 107, 211-218.	1.1	19
3	CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCs in patients with paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 179-192.	0.7	7
4	Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry. <i>British Journal of Haematology</i> , 2020, 189, 954-966.	1.2	16
5	Subtype-specific regulatory network rewiring in acute myeloid leukemia. <i>Nature Genetics</i> , 2019, 51, 151-162.	9.4	140
6	Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2019, 104, e94-e96.	1.7	14
7	Introduction to ICCS/ESCCA Consensus Guidelines to Detect GPI-deficient Cells in Paroxysmal Nocturnal Hemoglobinuria and Related Disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 12-13.	0.7	1
8	Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. <i>Haematologica</i> , 2018, 103, e345-e347.	1.7	18
9	Acquired Haemolytic Anaemias. , 2017, , 254-281.		2
10	High-sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells. <i>Current Protocols in Cytometry</i> , 2015, 72, 6.37.1-6.37.29.	3.7	25
11	Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature. <i>Cell Reports</i> , 2015, 12, 821-836.	2.9	63
12	Standardizing leucocyte PNH clone detection: An international study. , 2014, 86, 311-318.		12
13	Standardizing Leucocyte PNH clone detection: An international study. , 2014, , n/a-n/a.		17
14	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	0.6	66
15	Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. <i>British Journal of Haematology</i> , 2012, 158, 409-414.	1.2	48
16	Improved Outcomes of Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria with Eculizumab Therapy. <i>Blood</i> , 2012, 120, 3478-3478.	0.6	16
17	Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. <i>Blood</i> , 2011, 117, 6786-6792.	0.6	410
18	Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. <i>Haematologica</i> , 2010, 95, 567-573.	1.7	166

#	ARTICLE	IF	CITATIONS
19	Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 211-230.	0.7	195
20	Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2010, 149, 414-425.	1.2	137
21	The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. <i>British Journal of Haematology</i> , 2010, 149, 446-450.	1.2	122
22	The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 911.	0.9	33
23	Development and evaluation of a stabilized whole blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 47-55.	0.7	35
24	A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months.. <i>Blood</i> , 2009, 114, 1992-1992.	0.6	4
25	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2008, 359, 575-583.	13.9	518
26	A "epathogenetic" role for CMV in CD4+ LGL proliferations. <i>Blood</i> , 2008, 112, 4367-4368.	0.6	2
27	The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. <i>Cancer Research</i> , 2007, 67, 8444-8449.	0.4	284
28	The Role of Flow Cytometry in the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in the Clinical Laboratory. <i>Clinics in Laboratory Medicine</i> , 2007, 27, 577-590.	0.7	40
29	Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2007, 72B, 291-298.	0.7	39
30	Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2007, 137, 181-192.	1.2	130
31	Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2007, 92, e31-e33.	1.7	17
32	Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. <i>Blood</i> , 2006, 107, 2131-2137.	0.6	49
33	Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. <i>Nature Medicine</i> , 2006, 12, 846-851.	15.2	196
34	The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.. <i>Blood</i> , 2006, 108, 985-985.	0.6	41
35	Diagnosis and management of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2005, 106, 3699-3709.	0.6	652
36	Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2005, 106, 2559-2565.	0.6	199

#	ARTICLE	IF	CITATIONS
37	The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2005, 106, 1047-1047.	0.6	2
38	Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2004, 350, 552-559.	13.9	541
39	Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genetics and Cytogenetics, 2004, 148, 176-177.	1.0	7
40	Development and progression of a Philadelphia-chromosomeâ€“negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosomeâ€“positive chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 148, 170-173.	1.0	4
41	Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood, 2004, 103, 2027-2031.	0.6	64
42	Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.. Blood, 2004, 104, 172-172.	0.6	5
43	Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.. Blood, 2004, 104, 2823-2823.	0.6	3
44	Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood, 2003, 102, 3587-3591.	0.6	252
45	Immunophenotypic Analysis of PNH Cells. Current Protocols in Cytometry, 2002, 20, Unit 6.11.	3.7	7
46	The Glycosylphosphatidylinositol Anchor and Paroxysmal Nocturnal Haemoglobinuria/Aplasia Model. Acta Haematologica, 2002, 108, 219-230.	0.7	24
47	Monoclonal B lymphocytes with the characteristics of â€œindolentâ€“chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood, 2002, 100, 635-639.	0.6	305
48	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 2002, 100, 2289-2290.	0.6	207
49	Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 2001, 98, 29-35.	0.6	249
50	The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 2001, 112, 814-819.	1.2	103
51	Advances in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria. Clinical and Applied Immunology Reviews, 2001, 1, 315-330.	0.4	11
52	WaldenstrÃ¶m Macroglobulinemia. American Journal of Clinical Pathology, 2001, 116, 420-428.	0.4	137
53	Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry, 2000, 42, 223-233.	1.8	132
54	IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA. British Journal of Haematology, 2000, 108, 470-479.	1.2	63

#	ARTICLE	IF	CITATIONS
55	Paroxysmal Nocturnal Hemoglobinuria— the Selection of a Clone. Reviews in Clinical and Experimental Hematology, 2000, 4, 216-235.	0.1	1
56	Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood, 2000, 96, 3522-3528.	0.6	24
57	The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood, 2000, 96, 3880-3886.	0.6	78
58	High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment. Journal of Clinical Oncology, 2000, 18, 2843-2851.	0.8	91
59	Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. , 2000, 42, 223.		4
60	Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood, 2000, 96, 3522-3528.	0.6	11
61	The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood, 2000, 96, 3880-3886.	0.6	1
62	Analysis of T Cells in Paroxysmal Nocturnal Hemoglobinuria Provides Direct Evidence That Thymic T-Cell Production Declines With Age. Blood, 1999, 94, 2790-2799.	0.6	25
63	The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. British Journal of Haematology, 1999, 107, 148-153.	1.2	64
64	Lymphocyte Subset Analysis and Glycosylphosphatidylinositol Phenotype in Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 1799-1806.	0.6	39
65	Lymphocyte Subset Analysis and Glycosylphosphatidylinositol Phenotype in Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 1799-1806.	0.6	1
66	Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British Journal of Haematology, 1997, 97, 46-55.	1.2	165
67	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1838-1842.	6.7	25
68	Clonal CD3+CD8+ Large Granular Lymphocyte (LGL)/NK-Associated (NKa) Expansions: Primary Malignancies or Secondary Reactive Phenomena?. Leukemia and Lymphoma, 1995, 17, 303-311.	0.6	26
69	Immunophenotypic and DNA Genotypic Analysis of T-Cell and NK-Cell Subpopulations in Patients with B-Cell Chronic Lymphocytic Leukaemia (B-CLL). Leukemia and Lymphoma, 1995, 16, 307-318.	0.6	12
70	Persistent Clonal Expansions of CD3+TCR β ⁺ and CD3+TCR β ⁺ CD4 ⁺ CD8 ⁻ Lymphocytes Associated with Neutropenia. Leukemia and Lymphoma, 1994, 14, 429-440.	0.6	15
71	A biclonal large granular lymphocyte (LGL)/NK-associated (NKa) disorder of CD4 ⁺ and CD8 ⁺ lymphocyte subpopulations characterized by the simultaneous presence of distinct TCR rearrangements. British Journal of Haematology, 1994, 88, 629-632.	1.2	7
72	Transient and persistent expansions of large granular lymphocytes (LGL) and NK-associated (NKa) cells: the Yorkshire Leukaemia Group study. British Journal of Haematology, 1993, 83, 504-515.	1.2	43

#	ARTICLE	IF	CITATIONS
73	Human NK Cells in Health and Disease: Clinical, Functional, Phenotypic and DNA Genotypic Characteristics. <i>Leukemia and Lymphoma</i> , 1992, 7, 377-399.	0.6	32
74	A distinct large granular lymphocyte (LGL)/NK-associated (NKa) abnormality characterized by membrane CD4 and CD8 coexpression. <i>British Journal of Haematology</i> , 1992, 82, 494-501.	1.2	37
75	Abnormal CD45R expression in patients with common variable immunodeficiency and X-linked agammaglobulinaemia. <i>British Journal of Haematology</i> , 1992, 81, 160-166.	1.2	12
76	Patterns of CD16 and CD56 expression in persistent expansions of CD3+NKa+lymphocytes are predictive for clonal T-cell receptor gene rearrangements. <i>British Journal of Haematology</i> , 1991, 78, 368-377.	1.2	16
77	Patterns of Membrane Antigen Expression by AML Blasts: Quantitation and Histogram Analysis. <i>Leukemia and Lymphoma</i> , 1991, 5, 317-325.	0.6	1
78	T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: I, Diverse Patterns of Expression in Mature (Post-Thymic) T-Cell Proliferations. <i>Leukemia and Lymphoma</i> , 1991, 4, 27-37.	0.6	5
79	T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: II, Aberrant HLA-ABC Expression by CD45RA and CD45RO Cell Subpopulations of Mature CD4+T-Cell Leukaemias. <i>Leukemia and Lymphoma</i> , 1991, 4, 39-47.	0.6	0
80	Immunophenotypic Dissection of Normal Peripheral Blood NK Associated (NKa) Subpopulations by Flow Cytometry: Morphological Features and Relationships Between Membrane NKa (CD11b, CD 16, CD56) Tj ETQg 0,0 0 rgBT /Overlock <i>Leukemia and Lymphoma</i> , 1990, 2, 111-126.	0.6	28
81	Flow cytometric analysis of membrane CD11b, CD11c and CD14 expression in acute myeloid leukaemia: relationships with monocytic subtypes and the concept of relative antigen expression. <i>European Journal of Haematology</i> , 1990, 44, 24-29.	1.1	24
82	Validation of a single tube 3â€œcolour immature red blood cell screening assay for the detection and enumeration of small, medium and large paroxysmal nocturnal haemoglobinuria clones by flow cytometry. <i>International Journal of Laboratory Hematology</i> , 0, , .	0.7	1